It is suggested that routinely measured clinical characteristics may help identify populations with greater expected blood pressure response to sodium reduction, and salt sensitivity varied across age, SBP, and body mass index strata.
Abstract
Background
Hypertension guidelines generally recommend uniform sodium restriction although determinants of salt sensitivity, or sodium-blood pressure responsiveness, remain incompletely quantified. We estimated the population sodium-blood pressure dose-response, identified clinical modifiers, quantified high salt sensitivity prevalence, and derived the number needed to restrict sodium intake to prevent 1 cardiovascular event across clinical strata.
Methods
PubMed, Embase, and Cochrane were searched from inception to April 2025 for sodium intervention trials and observational studies. Blood pressure response was standardized per 50-mmol/d sodium difference. Random-effects metaregression evaluated clinical modifiers. A highly salt-sensitive phenotype was defined a priori as a systolic blood pressure (SBP) decrease ≥3 mm Hg per 50-mmol/d reduction.
Results
We included 160 studies (255 estimates; n=16 443). Each 50-mmol/d higher urinary sodium excretion was associated with 1.76-mm Hg higher SBP (95% CI, 1.54-1.98). Age and baseline SBP were the strongest modifiers (0.41 mm Hg per 5 years; 0.23 mm Hg per 5 mm Hg). Salt-sensitive phenotype prevalence rose from 12.5% (age <40 years) to 56.5% (>60 years) and from 16.3% (SBP <120 mm Hg) to 54.1% (≥130 mm Hg). Under a policy-relevant 100-mmol/d sodium reduction, number needed to restrict ranged from ≈1334 in younger, normotensive, lean individuals (age <60 years, SBP <130 mm Hg, and body mass index <25 kg/m2) to ≈87 in older adults with hypertension and elevated body mass index (age ≥60 years, SBP ≥130 mm Hg, and body mass index ≥25 kg/m2), a 15-fold gradient.
Conclusions
Salt sensitivity varied across age, SBP, and body mass index strata. These findings suggest that routinely measured clinical characteristics may help identify populations with greater expected blood pressure response to sodium reduction.
The dietary Na/K ratio emerged as an independent risk marker for hypertension, with significant pathogenic effects observed exclusively in older adults, and the Na/K ratio exhibited synergistic effects with central adiposity in elevating hypertension risk.
Jia-Nuo Yao· Theoretical and Natural Scie...· 0 citations
Baxdrostat, particularly at 2 mg, provides clinically meaningful BP reductions, and serious safety outcomes remain entirely comparable to control, which highlights a reassuring safety profile.
B. Khan, Muhammad Yahya, H. Khan et al.· Naunyn-Schmiedeberg's Archiv...· 1 citation
Systolic blood pressure exhibits a U-shaped relationship with all-cause mortality in patients with AF, balancing against a monotonic increase in ischemic stroke and intracranial haemorrhage at higher pressures, appears to optimize the balance between stroke prevention, bleeding risk, and survival.
E. Shahmohamadi, Alessandra Pina, Adrian D. Elliott et al.· Europace· 0 citations
Aldosterone dysregulation is common in patients with essential hypertension and is associated with suboptimal blood pressure control, and currently available treatments may not fully address aldosterone dysregulation.
Javed Butler, K. Hammonds, Muhammad Sameer Arshad et al.· American Journal of Cardiolo...· 0 citations
The identification of a high-risk SSI, based on 24-hour ABPM, is validated as a generalizable implementable approach for the clinical diagnosis of the SSBP, with a potential greater clinical diagnostic value in hypertensive versus normotensive individuals.
Xiangyu Zheng, Leonardo Máximo Cardoso, Christopher Dieffenthaller et al.· American Journal of Physiolo...· 0 citations
Baxdrostat lowers blood pressure and aldosterone levels in uncontrolled and resistant hypertension but increases potassium and modestly reduces eGFR, supporting careful laboratory monitoring and longer trials to evaluate long-term clinical outcomes.
A. Gadelmawla, A. Hageen, R. Rateb et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.